Bakker K, Brutten GJ Speech-related reaction times of stutterers and nonstutterers: diagnostic implications. J Speech Hear Disord. 1990 May;55(2):295-9.
Enderby PM, John A Therapy outcome measures in speech and language therapy: comparing performance between different providers. Int J Lang Commun Disord. 1999 Oct-Dec;34(4):417-29.
O'Brian S, Packman A, Onslow M, O'Brian N Measurement of stuttering in adults: comparison of stuttering-rate and severity-scaling methods. J Speech Lang Hear Res. 2004 Oct;47(5):1081-7.
Prasse JE, Kikano GE Stuttering: an overview. Am Fam Physician. 2008 May 1;77(9):1271-6. Review.
Prins D, Ingham RJ Evidence-based treatment and stuttering--historical perspective. J Speech Lang Hear Res. 2009 Feb;52(1):254-63. doi: 10.1044/1092-4388(2008/07-0111). Epub 2008 Aug 11. Review. Erratum in: J Speech Lang Hear Res. 2009 Apr;52(2):570.
SHERMAN D Clinical and experimental use of the Iowa Scale of Severity of Stuttering. J Speech Hear Disord. 1952 Sep;17(3):316-20.
Yairi E Subtyping stuttering I: a review. J Fluency Disord. 2007;32(3):165-96. Epub 2007 Apr 24. Review.
Computerized Based Analysis for Detection and Severity Assessment of Stuttering
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
